David Roofeh, MD
Rheumatology · Ann Arbor, MINPI 1396156626
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,280 of the $8,186 with a category attached, or 64.5%. Boehringer Ingelheim accounts for 65.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $5,280 and has fallen 96.5% since, to $187 in 2025.
Across 19 payments — averaging $430.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$5K
- CSL Behring$3K
- Novartis$187
Across 21 payments — averaging $11,627 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$153K
- Mitsubishi Tanabe Pharma Development America, Inc.$58K
- Tanabe Pharma America, Inc.$34K
What the payments were for
- Consulting fees$5,28064%
- Travel & lodging$1,75221%
- Food & beverage$1,15414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 3 | $5,393 |
| CSL Behring | 14 | $2,606 |
| Novartis | 2 | $187 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,186 in reported general payments places this provider in the 70th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 15 | $68,135 |
| Orencia ClickjectAbatacept | 11 | $59,528 |
| Mycophenolate Mofetil | 22 | $6,290 |
| MethotrexateMethotrexate Sodium | 24 | $834 |
| Hydroxychloroquine Sulfate | 19 | $553 |
| Colchicine | 17 | $442 |
| Prednisone | 38 | $419 |
| Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen | 11 | $66 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $50 |
| Alendronate Sodium | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Ann Arbor
- Dinesh KhannaAnn Arbor$1.2M
- Elena SchiopuAnn Arbor$180K
- Daniel ClauwAnn Arbor$102K
- Katherine ChakrabartiAnn Arbor$82K
- Puja KhannaAnn Arbor$78K
- Joanne KahlenbergAnn Arbor$74K
- John VargaAnn Arbor$64K
- Samardeep GuptaAnn Arbor$58K
- Jason KnightAnn Arbor$38K
- Sheeja FrancisAnn Arbor$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.